Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-04-20

FDA Approved: OXYCONTIN — Supplemental Application (Purdue Pharma LP)

View source ↗

Summary

The FDA approved Purdue Pharma LP's supplemental application for OXYCONTIN (oxycodone hydrochloride), updating labeling as part of the supplemental submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OXYCONTIN (OXYCODONE HYDROCHLORIDE)

Snippet

SUPPL AP for OXYCONTIN (OXYCODONE HYDROCHLORIDE)